What changed in this filing

/stocks — the workspaceLOADING

Item 2. Management’s Discussion and Analysis

2022-11-14 compared with 2022-08-15 · 37 added, 42 removed, 115 unchanged (41% of the section changed)

47 unchanged sentences

complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment.

To date, we have not generated

any revenue and we have incurred net losses.

Our net losses were approximately $4.6 million and $1.9 million for the years ended December

31, 2021 and 2020, respectively and $2.7 million and $1.3 million for the six months ended June 30, 2022 and 2021, respectively.

date, we have not generated any revenue and we have incurred net losses.

Our net losses were approximately $4.6 million and $1.9

million for the years ended December 31, 2021 and 2020, respectively and $5.0 million and $2.2 million for the nine months ended

September 30, 2022 and 2021, respectively.

net losses have resulted from costs incurred in developing the drug in our pipeline, planning and preparing for clinical trials and general

8 unchanged sentences

We will also experience increased costs associated with operating as a public company.

of Operations for the Three Months Ended June 30, 2022 and 2021

of Operations for the Three Months Ended September 30, 2022 and 2021

and Development Expenses

Research and development expenses

increased by $76,716 or 14%, to $633,250 for the three months ended June 30, 2022 from $556,534 for the three months ended June 30, 2021.

The increase was primarily the result of an increase in cash compensation.

General and Administrative Expenses

General and administrative expenses decreased by $56,854, or 29%, to $140,057

for the three months ended June 30, 2022 from $196,911 for the three months ended June 30, 2021.

The decrease was primarily the result

of a decrease in financing and corporate costs.

Results of Operations for the Six Months Ended

June 30, 2022 and 2021

Research and Development Expenses

Research and development expenses increased by $1,455,560, or 174%, to

$2,294,071 for the six months ended June 30, 2022 from $838,511 for the six months ended June 30, 2021.

The increase was primarily the

result of an increase in cash compensation, clinical, and manufacturing expenses.

and development expenses increased by $1,066,397, or 162%, to $1,723,493 for the three months ended September 30, 2022 from $657,096

for the three months ended September 30, 2021.

The increase was primarily the result of an increase in stock

compensation, clinical, and manufacturing expenses.

and Administrative Expenses

General and administrative expenses decreased by $47,101, or 9%, to $468,439

for the six months ended June 30, 2022 from $515,540 for the six months ended June 30, 2021.

The decrease was primarily the result of

a decrease in financing and corporate costs.

and administrative expenses increased by $449,978, or 215%, to $659,568 for the three months ended September 30, 2022 from $209,590

for the three months ended September 30, 2021.

The increase was primarily the result of an increase in stock compensation and

financing expenses.

of Operations for the Nine Months Ended September 30, 2022 and 2021

and Development Expenses

and development expenses increased by $2,521,957, or 169%, to $4,017,564 for the nine months ended September 30, 2022 from $1,495,607

for the nine months ended September 30, 2021.

The increase was primarily the result of an increase in cash compensation, clinical, and

manufacturing expenses.

and Administrative Expenses

and administrative expenses increased by $402,877, or 56%, to $1,128,007 for the nine months ended September 30, 2022 from $725,130 for

the nine months ended September 30, 2021.

The increase was primarily the result of an increase in stock compensation and financing expenses.

and Capital Resources

10 unchanged sentences

may require us to raise additional capital.

As of June 30, 2022 and December 31, 2021, our principal source of liquidity was our cash,

which totaled $17,187,890 and $27,204,269, respectively, and additional loans and accrued unreimbursed expenses from related parties.

As of September 30, 2022 and December 31, 2021, our principal source of liquidity was our

cash, which totaled $15,638,087 and $27,204,269, respectively, and additional loans and accrued unreimbursed expenses from related parties.

Historically, our principal sources of cash have included proceeds from the sale of common stock and preferred stock and related party

2 unchanged sentences

be for continuing operations, funding of research and development, including our clinical trials, and general working capital requirements.

Flow Activities for the Six Months Ended June 30, 2022 and 2021

We incurred net losses of $2,715,701 and $1,346,753 during the six month

periods ended June 30, 2022 and 2021, respectively.

The increase was primarily the result of an increase in cash compensation, clinical,

and manufacturing expenses.

Net cash used in operating activities

was $2,480,163 for the six months ended June 30, 2022 and $1,132,589 for the six months ended June 30, 2021.

We did not use or generate cash

from investing activities during the six months ended June 30, 2022 and June, 2021.

We used a total of $7,536,216

cash for the stock buy back program, net of costs, during the six months ended June 30, 2022 and used and generated cash netting a total

of $2,272,846 from financing activities during the six months ended June 30, 2021.

Flow Activities for the Nine Months Ended September 30, 2022 and 2021

incurred net losses of $5,034,725 and $2,209,871 during the nine month periods ended September 30, 2022 and 2021, respectively.

was primarily the result of an increase in cash compensation, financing, clinical, and manufacturing expenses.

cash used in operating activities was $4,029,966 for the nine months ended September 30, 2022 and $2,027,228 for the nine months ended

September 30, 2021.

did not use or generate cash from investing activities during the nine months ended September 30, 2022 and September 30, 2021.

used a total of $7,536,216 cash for the stock buy back program, net of costs, during the nine months ended September 30, 2022 and used

and generated cash netting a total of $2,272,846 from financing activities during the nine months ended September 30, 2021.

Obligations and Commitments

of March 31, 2022, we did not have any material contractual obligations, other than employment and shareholder agreements, license for

GP2 from HJF, and manufacturing and clinical trial obligations.

of September 30, 2022, we did not have any material contractual obligations, other than employment and shareholder agreements, license

for GP2 from HJF, and manufacturing and clinical trial obligations.

Sheet Arrangements

of June 30, 2022, we did not have any off-balance sheet arrangements as described by Item 303(a)(4) of Regulation S-K.

of September 30, 2022, we did not have any off-balance sheet arrangements as described by Item 303(a)(4) of Regulation S-K.

Accounting Policies and Estimates

10 unchanged sentences

Accounting Pronouncements

of June 30, 2022, there were no recent accounting pronouncements applicable to our business.

of September 30, 2022, there were no recent accounting pronouncements applicable to our business.

April 5, 2012, the JOBS Act was enacted.

24 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 2. Management’s Discussion and Analysis